Maintenance Therapy with Decitabine after Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukemia and Myelodysplastic Syndrome

Biology of Blood and Marrow Transplantation

Volumn 21, Issue 10, 2015, Pages 1761-1769

  Pusic, Iskra ^a   Choi, Jaebok ^a   Fiala, Mark A ^a   Gao, Feng ^a   Holt, Matthew ^a   Cashen, Amanda F ^a   Vij, Ravi ^a   Abboud, Camille N ^a   Stockerl Goldstein, Keith E ^a   Jacoby, Meghan A ^a   Uy, Geoffrey L ^a   Westervelt, Peter ^a   DiPersio, John F ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Acute leukemia; Decitabine; Maintenance; Myelodysplastic syndrome; Stem cell transplantation

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; DECITABINE; METHOTREXATE; TACROLIMUS; TRANSCRIPTION FACTOR FOXP3; ANTINEOPLASTIC ANTIMETABOLITE; AZACITIDINE;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE MYELOBLASTIC LEUKEMIA; ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ALLOTRANSPLANTATION; ANEMIA; ARTICLE; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DIARRHEA; DISEASE ASSOCIATION; DISEASE CONTROL; DRUG DOSE ESCALATION; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; FEMALE; GRAFT VERSUS LEUKEMIA EFFECT; HUMAN; HYPOKALEMIA; HYPONATREMIA; HYPOTENSION; INCIDENCE; INFECTIOUS COMPLICATION; KIDNEY FAILURE; LOW DRUG DOSE; LYMPHOCYTOPENIA; MAINTENANCE THERAPY; MALE; MAXIMUM PERMISSIBLE DOSE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MINIMAL RESIDUAL DISEASE; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; NEUROPATHY; NEUTROPENIA; OPTIMAL DRUG DOSE; PAIN; PERSONAL EXPERIENCE; PROSPECTIVE STUDY; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; RELAPSE; REMISSION; SEPSIS; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT RESPONSE; ALLOGRAFT; ANALOGS AND DERIVATIVES; CHEMICALLY INDUCED; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DOSE RESPONSE; GASTROINTESTINAL DISEASE; GRAFT VS HOST DISEASE; HEMATOLOGIC DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; INTRAVENOUS DRUG ADMINISTRATION; LEUKEMIA, MYELOID, ACUTE; MAINTENANCE CHEMOTHERAPY; MULTIMODALITY CANCER THERAPY; MYELODYSPLASTIC SYNDROMES; PHASE 1 CLINICAL TRIAL; PROCEDURES; YOUNG ADULT;

ADULT; AGED; ALLOGRAFTS; ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GASTROINTESTINAL DISEASES; GRAFT VS HOST DISEASE; HEMATOLOGIC DISEASES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFUSIONS, INTRAVENOUS; LEUKEMIA, MYELOID, ACUTE; MAINTENANCE CHEMOTHERAPY; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84941317871     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2015.05.026     Document Type: Article

References (45)

1. Solomon S.R., Sizemore C.A., Sanacore M., et al. Total body irradiation-based myeloablative haploidentical stem cell transplantation is a safe and effective alternative to unrelated donor transplantation in patients without matched sibling donors. Biol Blood Marrow Transplant 2015, 21:1299-1307.
2. Malard F., Milpied N., Blaise D., et al. Effect of graft source on unrelated donor hemopoietic stem cell transplantation in adults with acute myeloid leukemia after reduced-intensity or nonmyeloablative conditioning: a study from the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire. Biol Blood Marrow Transplant 2015, 21:1059-1067.
3. Majhail N.S., Chitphakdithai P., Logan B., et al. Significant improvement in survival after unrelated donor hematopoietic cell transplantation in the recent era. Biol Blood Marrow Transplant 2015, 21:142-150.
4. Barrett A.J., Savani B.N. Stem cell transplantation with reduced-intensity conditioning regimens: A review of ten years experience with new transplant concepts and new therapeutic agents. Leukemia 2006, 20:1661-1672.
5. Duncan C.N., Majhail N.S., Brazauskas R., et al. Long-term survival and late effects among one-year survivors of second allogeneic hematopoietic cell transplantation for relapsed acute leukemia and myelodysplastic syndromes. Biol Blood Marrow Transplant 2015, 21:151-158.
6. Oran B., Giralt S., Couriel D., et al. Treatment of AML and MDS relapsing after reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation. Leukemia 2007, 21:2540-2544.
7. Bishop M.R., Alyea E.P., Cairo M.S., et al. National Cancer Institute's First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: summary and recommendations from the organizing committee. Biol Blood Marrow Transplant 2011, 17:443-454.
8. de Lima M., Porter D.L., Battiwalla M., et al. Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse After Hematopoietic Stem Cell Transplantation: part III. Prevention and treatment of relapse after allogeneic transplantation. Biol Blood Marrow Transplant 2014, 20:4-13.
9. Bejanyan N., Weisdorf D.J., Logan B.R., et al. Survival of patients with acute myeloid leukemia relapsing after allogeneic hematopoietic cell transplantation: a center for international blood and marrow transplant research study. Biol Blood Marrow Transplant 2015, 21:454-459.
10. Porter D.L., Collins R.H., Hardy C., et al. Treatment of relapsed leukemia after unrelated donor marrow transplantation with unrelated donor leukocyte infusions. Blood 2000, 95:1214-1221.
11. Mielcarek M., Storer B.E., Flowers M.E.D., et al. Outcomes among patients with recurrent high-risk hematologic malignancies after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2007, 13:1160-1168.
12. Pollyea D.A., Artz A.S., Stock W., et al. Outcomes of patients with AML and MDS who relapse or progress after reduced intensity allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 2007, 40:1027-1032.
13. de Lima M., Giralt S., Thall P.F., et al. Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: a dose and schedule finding study. Cancer 2010, 116:5420-5431.
14. Jabbour E., Giralt S., Kantarjian H., et al. Low-dose azacitidine after allogeneic stem cell transplantation for acute leukemia. Cancer 2009, 115:1899-1905.
15. Hourigan C.S., McCarthy P., de Lima M. Back to the future! The evolving role of maintenance therapy after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2014, 20:154-163.
16. Schroeder T., Rachlis E., Bug G., et al. Treatment of acute myeloid leukemia or myelodysplastic syndrome relapse after allogeneic stem cell transplantation with azacitidine and donor lymphocyte infusions-a retrospective multicenter analysis from the German Cooperative Transplant Study Group. Biol Blood Marrow Transplant 2015, 21:653-660.
17. Schroeder T., Czibere A., Platzbecker U., et al. Azacitidine and donor lymphocyte infusions as first salvage therapy for relapse of AML or MDS after allogeneic stem cell transplantation. Leukemia 2013, 27:1229-1235.
18. Schroeder T., Frobel J., Cadeddu R.P., et al. Salvage therapy with azacitidine increases regulatory T cells in peripheral blood of patients with AML or MDS and early relapse after allogeneic blood stem cell transplantation. Leukemia 2013, 27:1910-1913.
19. Sanchez-Abarca L.I., Gutierrez-Cosio S., Santamaria C., et al. Immunomodulatory effect of 5-azacytidine (5-azaC): potential role in the transplantation setting. Blood 2010, 115:107-121.
20. Jones P.A., Taylor S.M. Cellular differentiation, cytidine analogs and DNA methylation. Cell 1980, 20:85-93.
21. Strathdee G., Brown R. Epigenetic cancer therapies: DNA methyltransferase inhibitors. Expert Opin Investig Drugs 2002, 11:747-754.
22. Sacchi S., Kantarjian H.M., O'Brien S., et al. Chronic myelogenous leukemia in nonlymphoid blastic phase: analysis of the results of first salvage therapy with three different treatment approaches for 162 patients. Cancer 1999, 86:2632-2641.
23. Issa J.P., Garcia-Manero G., Giles F.J., et al. Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies. Blood 2004, 103:1635-1640.
24. Kantarjian H.M., O'Brien S., Huang X., et al. Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome: comparison with historical experience. Cancer 2007, 109:1133-1137.
25. Kantarjian H., Issa J.P., Rosenfeld C.S., et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 2006, 106:1794-1803.
26. Lubbert M., Wijermans P., Kunzmann R., et al. Cytogenetic responses in high-risk myelodysplastic syndrome following low-dose treatment with the DNA methylation inhibitor 5-aza-2'-deoxycytidine. Br J Haematol 2001, 114:349-357.
27. Wijermans P., Lubbert M., Verhoef G., et al. Low-dose 5-aza-2'-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients. J Clin Oncol 2000, 18:956-962.
28. Wijermans P.W., Lubbert M., Verhoef G., et al. An epigenetic approach to the treatment of advanced MDS; the experience with the DNA demethylating agent 5-aza-2'-deoxycytidine (decitabine) in 177 patients. Ann Hematol 2005, 84(Suppl 1):9-17.
29. Cashen A.F., Schiller G.J., O'Donnell M.R., DiPersio J.F. Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia. J Clin Oncol 2010, 28:556-561.
30. Kantarjian H.M., Thomas X.G., Dmoszynska A., et al. Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol 2012, 30:2670-2677.
31. Choi J., Ritchey J., DiPersio J. Generation of Treg-like cells from CD4+CD25- T cells via epigenetic modification using a demethylating agent decitabine. [ASH Annual Meeting Abstracts] Blood 2007, 110:62.
32. Choi J., Ritchey J., Prior J.L., et al. In vivo administration of hypomethylating agents mitigate graft-versus-host disease without sacrificing graft-versus-leukemia. Blood 2010, 116:129-139.
33. Choi J., Ziga E.D., Ritchey J., et al. IFNgammaR signaling mediates alloreactive T-cell trafficking and GVHD. Blood 2012, 120:4093-4103.
34. Magenau J.M., Qin X., Tawara I., et al. Frequency of CD4(+)CD25(hi)FOXP3(+) regulatory T cells has diagnostic and prognostic value as a biomarker for acute graft-versus-host-disease. Biol Blood Marrow Transplant 2010, 16:907-914.
35. Goodyear O.C., Dennis M., Jilani N.Y., et al. Azacitidine augments expansion of regulatory T cells after allogeneic stem cell transplantation in patients with acute myeloid leukemia (AML). Blood 2012, 119:3361-3369.
36. Coral S., Sigalotti L., Gasparollo A., et al. Prolonged upregulation of the expression of HLA class I antigens and costimulatory molecules on melanoma cells treated with 5-aza-2'-deoxycytidine (5-AZA-CdR). J Immunother 1999, 22:16-24.
37. Hambach L., Ling K.W., Pool J., et al. Hypomethylating drugs convert HA-1-negative solid tumors into targets for stem cell-based immunotherapy. Blood 2009, 113:2715-2722.
38. Liu Y., Kuick R., Hanash S., Richardson B. DNA methylation inhibition increases T cell KIR expression through effects on both promoter methylation and transcription factors. Clin Immunol 2009, 130:213-224.
39. Stubig T., Badbaran A., Luetkens T., et al. 5-azacytidine promotes an inhibitory T-cell phenotype and impairs immune mediated antileukemic activity. Mediators Inflamm 2014, 2014:418292.
40. Filipovich A.H., Weisdorf D., Pavletic S., et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005, 11:945-956.
41. Lal G., Bromberg J.S. Epigenetic mechanisms of regulation of Foxp3 expression. Blood 2009, 114:3727-3735.
42. Kim Y.C., Bhairavabhotla R., Yoon J., et al. Oligodeoxynucleotides stabilize Helios-expressing Foxp3+ human T regulatory cells during in vitro expansion. Blood 2012, 119:2810-2818.
43. Kim J., Bhattacharjee R., Khalyfa A., et al. DNA methylation in inflammatory genes among children with obstructive sleep apnea. Am J Respir Crit Care Med 2012, 185:330-338.
44. Fine J.P., Gray R.J. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999, 94:496-509.
45. Momparler R.L., Rivard G.E., Gyger M. Clinical trial on 5-aza-2'-deoxycytidine in patients with acute leukemia. Pharmacol Ther 1985, 30:277-286.